AspirinAnti-Inflammatory Agents, Non-SteroidalCyclooxygenase 2 InhibitorsIbuprofenCyclooxygenase InhibitorsDiclofenacNaproxenGastrointestinal DiseasesPlatelet Aggregation InhibitorsProstaglandin-Endoperoxide SynthasesCyclooxygenase 2AcetaminophenPiroxicamKetoprofenCyclooxygenase 1Stomach UlcerThiazinesGastrointestinal HemorrhagePeptic UlcerSulfonesSulfonamidesPyrazolesLactonesEtodolacPeptic Ulcer HemorrhageAnalgesics, Non-NarcoticThromboxane B2SalicylatesDrug Therapy, CombinationIndomethacinRisk FactorsGastric MucosaTiclopidineSulindacOsteoarthritisMisoprostolAnti-Ulcer AgentsNitrobenzenesArthritisProton Pump InhibitorsFlurbiprofenKetorolacPlatelet AggregationDinoprostoneStomach DiseasesDrug HypersensitivityDrug InteractionsDose-Response Relationship, DrugDuodenal UlcerIsoenzymesPlatelet Function TestsDouble-Blind MethodProstaglandinsUpper Gastrointestinal TractSafety-Based Drug WithdrawalsIntestinal DiseasesSodium SalicylateProspective StudiesTreatment OutcomeCase-Control StudiesDrug PrescriptionsAsthma, Aspirin-InducedBlood PlateletsAnalgesicsUlcerDrug UtilizationChemopreventionAnticarcinogenic AgentsButanonesRandomized Controlled Trials as TopicTolmetinPainColorectal NeoplasmsHistamine H2 AntagonistsPhenylpropionatesTablets, Enteric-CoatedCohort StudiesClonixinRisk AssessmentAnticoagulantsTime FactorsHelicobacter InfectionsHelicobacter pyloriFibrinolytic AgentsAnti-Inflammatory AgentsMefenamic AcidWarfarinMembrane ProteinsGrowth Differentiation Factor 15IncidenceArthritis, RheumatoidHemorrhageDrug Administration ScheduleRheumatic DiseasesRiskThiazolesCardiovascular DiseasesBleeding TimeOdds RatioMyocardial Infarction